Hilmar Schiller

882 total citations
34 papers, 548 citations indexed

About

Hilmar Schiller is a scholar working on Molecular Biology, Oncology and Pharmacology. According to data from OpenAlex, Hilmar Schiller has authored 34 papers receiving a total of 548 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 12 papers in Oncology and 12 papers in Pharmacology. Recurrent topics in Hilmar Schiller's work include Pharmacogenetics and Drug Metabolism (11 papers), Drug Transport and Resistance Mechanisms (8 papers) and Photosynthetic Processes and Mechanisms (8 papers). Hilmar Schiller is often cited by papers focused on Pharmacogenetics and Drug Metabolism (11 papers), Drug Transport and Resistance Mechanisms (8 papers) and Photosynthetic Processes and Mechanisms (8 papers). Hilmar Schiller collaborates with scholars based in Switzerland, United States and Germany. Hilmar Schiller's co-authors include Holger Dau, Kenichi Umehara, Felix Huth, Gian Camenisch, Horst Senger, Heike Gutmann, Patrick Bouic, Shigetoh Miyachi, Hideaki Miyashita and Bernd Rosenkranz and has published in prestigious journals such as Biochemistry, FEBS Letters and American Journal of Physiology-Cell Physiology.

In The Last Decade

Hilmar Schiller

33 papers receiving 541 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hilmar Schiller Switzerland	14	300	112	84	79	76	34	548
Torsten Herbertz United States	15	446 1.5×	42 0.4×	121 1.4×	28 0.4×	69 0.9×	28	1.1k
Joel A. Krauser United States	16	365 1.2×	241 2.2×	130 1.5×	43 0.5×	23 0.3×	26	854
Aldo Gutiérrez United Kingdom	15	457 1.5×	231 2.1×	97 1.2×	16 0.2×	35 0.5×	20	758
Heinz Schleyer United States	15	429 1.4×	176 1.6×	46 0.5×	32 0.4×	114 1.5×	41	898
David L. Roberts United States	6	591 2.0×	261 2.3×	104 1.2×	10 0.1×	38 0.5×	7	907
Feifei Gu United States	13	479 1.6×	22 0.2×	17 0.2×	158 2.0×	130 1.7×	14	692
Salvatore Di Bernardo Italy	18	1.1k 3.7×	23 0.2×	38 0.5×	145 1.8×	45 0.6×	24	1.6k
Thomas M. Shea United States	11	537 1.8×	273 2.4×	117 1.4×	9 0.1×	66 0.9×	16	1.1k
Wolfgang E. Trommer Germany	17	715 2.4×	48 0.4×	65 0.8×	15 0.2×	41 0.5×	83	1.2k
Eleanore Seibert United States	11	612 2.0×	201 1.8×	120 1.4×	44 0.6×	23 0.3×	13	943

Countries citing papers authored by Hilmar Schiller

Since Specialization

Citations

This map shows the geographic impact of Hilmar Schiller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hilmar Schiller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hilmar Schiller more than expected).

Fields of papers citing papers by Hilmar Schiller

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hilmar Schiller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hilmar Schiller. The network helps show where Hilmar Schiller may publish in the future.

Co-authorship network of co-authors of Hilmar Schiller

This figure shows the co-authorship network connecting the top 25 collaborators of Hilmar Schiller. A scholar is included among the top collaborators of Hilmar Schiller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hilmar Schiller. Hilmar Schiller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Argikar, Upendra A., et al.. (2025). Clinical Significance of Drug–Drug Interaction Studies During Therapeutic Peptide Drug Development: Follow‐Up Investigation of Therapeutic Peptides Approved Between 2021 and 2024. Clinical and Translational Science. 18(7). 1 indexed citations

Huth, Felix, et al.. (2025). Evaluation of various experimental conditions and mechanistic static versus dynamic models to predict time-dependent CYP3A4/5 inhibition potential of drugs. Drug Metabolism and Disposition. 53(8). 100117–100117.

Ji, Yan, Hilmar Schiller, Michelle Quinlan, et al.. (2024). Use of Pharmacokinetic and Pharmacodynamic Data to Develop the CDK4/6 Inhibitor Ribociclib for Patients with Advanced Breast Cancer. Clinical Pharmacokinetics. 63(2). 155–170. 2 indexed citations

Argikar, Upendra A., Kari R. Fonseca, Constanze Hilgendorf, et al.. (2023). Industry Perspective on Therapeutic Peptide Drug–Drug Interaction Assessments During Drug Development: A European Federation of Pharmaceutical Industries and Associations White Paper. Clinical Pharmacology & Therapeutics. 113(6). 1199–1216. 15 indexed citations

Coutant, David E., David W. Boulton, Upendra P. Dahal, et al.. (2022). Therapeutic Protein Drug Interactions: A White Paper From the International Consortium for Innovation and Quality in Pharmaceutical Development. Clinical Pharmacology & Therapeutics. 113(6). 1185–1198. 11 indexed citations

Schiller, Hilmar, Felix Huth, Anton Drollmann, et al.. (2022). Novel Bruton's tyrosine kinase inhibitor remibrutinib: Assessment of drug-drug interaction potential as a perpetrator of cytochrome P450 enzymes and drug transporters and the impact of covalent binding on possible drug interactions. European Journal of Pharmaceutical Sciences. 172. 106155–106155. 4 indexed citations

Huth, Felix, Hilmar Schiller, Yi Jin, et al.. (2021). Novel Bruton’s Tyrosine Kinase inhibitor remibrutinib: Drug‐drug interaction potential as a victim of CYP3A4 inhibitors based on clinical data and PBPK modeling. Clinical and Translational Science. 15(1). 118–129. 6 indexed citations

Samant, Tanay S., Felix Huth, Kenichi Umehara, et al.. (2020). Ribociclib Drug‐Drug Interactions: Clinical Evaluations and Physiologically‐Based Pharmacokinetic Modeling to Guide Drug Labeling. Clinical Pharmacology & Therapeutics. 108(3). 575–585. 25 indexed citations

Umehara, Kenichi, et al.. (2019). Examining P-gp efflux kinetics guided by the BDDCS – Rational selection of in vitro assay designs and mathematical models. European Journal of Pharmaceutical Sciences. 132. 132–141. 8 indexed citations

10.

Poller, Birk, Ralph Woessner, Avantika Barve, et al.. (2019). Fevipiprant has a low risk of influencing co-medication pharmacokinetics: Impact on simvastatin and rosuvastatin in different SLCO1B1 genotypes. Pulmonary Pharmacology & Therapeutics. 57. 101809–101809. 8 indexed citations

11.

Umehara, Kenichi, Felix Huth, Yi Jin, et al.. (2019). Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions. Drug Metabolism and Personalized Therapy. 34(2). 29 indexed citations

12.

Umehara, Kenichi, Gareth Williams, Thomas Faller, et al.. (2017). Assessment of the pulmonary CYP1A1 metabolism of mavoglurant (AFQ056) in rat. Xenobiotica. 48(8). 793–803. 4 indexed citations

13.

Umehara, Kenichi, Felix Huth, Helen Gu, et al.. (2017). Estimation of fractions metabolized by hepatic CYP enzymes using a concept of inter-system extrapolation factors (ISEFs) – a comparison with the chemical inhibition method. Drug Metabolism and Personalized Therapy. 32(4). 191–200. 6 indexed citations

14.

Umehara, Kenichi, et al.. (2016). Improvement of the chemical inhibition phenotyping assay by cross-reactivity correction. Drug Metabolism and Personalized Therapy. 31(4). 221–228. 16 indexed citations

15.

Barve, Avantika, Hanns-Christian Tillmann, Georges Imbert, et al.. (2016). Impact of co-administration of fevipiprant (QAW039) and SLCO1B1 genotype on the PK of simvastatin and rosuvastatin. PA1108–PA1108. 1 indexed citations

16.

Umehara, Kenichi, Markus Zollinger, Elizabeth Kigondu, et al.. (2016). Esterase phenotyping in human liverin vitro: specificity of carboxylesterase inhibitors. Xenobiotica. 46(10). 862–867. 18 indexed citations

17.

Manevski, Nenad, Piet Swart, Kamal K. Balavenkatraman, et al.. (2014). Phase II Metabolism in Human Skin: Skin Explants Show Full Coverage for Glucuronidation, Sulfation, N-Acetylation, Catechol Methylation, and Glutathione Conjugation. Drug Metabolism and Disposition. 43(1). 126–139. 37 indexed citations

18.

Fasinu, Pius S., Heike Gutmann, Hilmar Schiller, Patrick Bouic, & Bernd Rosenkranz. (2013). The potential ofHypoxis hemerocallideafor herb–drug interaction. Pharmaceutical Biology. 51(12). 1499–1507. 24 indexed citations

19.

Fasinu, Pius S., et al.. (2012). The Potential of Sutherlandia frutescens for Herb-Drug Interaction. Drug Metabolism and Disposition. 41(2). 488–497. 34 indexed citations

20.

Gödecke, Stefanie, et al.. (2005). Do rat cardiac myocytes release ATP on contraction?. American Journal of Physiology-Cell Physiology. 289(3). C609–C616. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact